Mar 27, 2026 4:12pm EDT Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
Mar 24, 2026 8:00am EDT Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
Mar 12, 2026 7:30am EDT Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
Mar 06, 2026 7:47am EST Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Jan 13, 2026 7:47am EST Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
Dec 11, 2025 7:47am EST Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
Dec 05, 2025 7:30am EST Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
Dec 04, 2025 7:47am EST Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
Nov 06, 2025 4:02pm EST Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
